blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2641590

EP2641590 - Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.02.2018
Database last updated on 21.05.2024
FormerThe patent has been granted
Status updated on  03.03.2017
FormerGrant of patent is intended
Status updated on  13.01.2017
FormerExamination is in progress
Status updated on  21.12.2016
FormerGrant of patent is intended
Status updated on  16.12.2016
Most recent event   Tooltip26.06.2020Lapse of the patent in a contracting state
New state(s): CY, MK		published on 29.07.2020  [2020/31]
Applicant(s)For all designated states
Urogen Pharma Ltd.
9 Ha`Tassiya Street
4365007 Ra`anana / IL
[2016/42]
Former [2013/39]For all designated states
Telormedix SA
Via della Posta 10
6934 Bioggio / CH
Inventor(s)01 / Leoni, Lorenzo
Via Perdaglie 32
6527 Lodrino / CH
02 / Maj, Roberto
Via Favia 7
21047 Saronno / IT
03 / Pattarino, Franco
Via Genova 77
10126 Torino / IT
04 / Vecchio, Carlo
Via Comignago 2B Revislate
28010 Veruno / IT
 [2013/39]
Representative(s)Graf von Stosch, Andreas, et al
Graf von Stosch
Patentanwaltsgesellschaft mbH
Prinzregentenstraße 22
80538 München / DE
[2017/14]
Former [2013/39]Graf von Stosch, Andreas, et al
Graf von Stosch Patentanwaltsgesellschaft mbH Prinzregentenstrasse 22
80538 München / DE
Application number, filing date13001958.105.02.2010
[2013/39]
Priority number, dateWO2009EP0083406.02.2009         Original published format: PCT/EP2009/000834
[2013/39]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2641590
Date:25.09.2013
Language:EN
[2013/39]
Type: B1 Patent specification 
No.:EP2641590
Date:05.04.2017
Language:EN
[2017/14]
Search report(s)(Supplementary) European search report - dispatched on:EP23.08.2013
ClassificationIPC:A61K9/00, A61K47/12, A61K31/4745, A61P13/10, A61P35/00, // A61K47/10, A61K47/34, A61K47/40
[2016/34]
CPC:
A61K47/40 (EP,IL,KR,US); A61K31/4745 (EP,IL,KR,US); A61K47/10 (EP,KR,US);
A61K47/12 (EP,IL,KR,US); A61K47/34 (EP,IL,KR,US); A61K9/00 (IL);
A61K9/0014 (EP,KR,US); A61K9/0034 (EP,KR,US); A61P13/00 (EP);
A61P13/10 (EP); A61P17/00 (EP); A61P17/12 (EP);
A61P35/00 (EP); Y02A50/30 (EP) (-)
Former IPC [2013/39]A61K9/00, A61K47/12, A61K31/4745, A61P13/10, A61P35/00, // A61K47/10, A61K47/40
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2013/39]
Extension statesAL15.04.2013
BA15.04.2013
RS15.04.2013
TitleGerman:Pharmazeutische Zusammensetzungen mit Imidazochinolin(aminen) und Derivativen daraus zur lokalen Verabreichung[2013/39]
English:Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration[2013/39]
French:Compositions pharmaceutiques comprenant des imidazoquinolines (amines) et ses dérivés appropriés pour une administration locale[2013/39]
Examination procedure15.04.2013Examination requested  [2013/39]
25.03.2014Amendment by applicant (claims and/or description)
16.02.2016Despatch of a communication from the examining division (Time limit: M04)
24.06.2016Reply to a communication from the examining division
10.08.2016Communication of intention to grant the patent
12.12.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
12.12.2016Fee for grant paid
12.12.2016Fee for publishing/printing paid
12.01.2017Information about intention to grant a patent
12.01.2017Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP10703023.1  / EP2393474
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20100703023) is  18.07.2012
Opposition(s)08.01.2018No opposition filed within time limit [2018/11]
Fees paidRenewal fee
15.04.2013Renewal fee patent year 03
15.04.2013Renewal fee patent year 04
30.12.2013Renewal fee patent year 05
16.12.2014Renewal fee patent year 06
26.02.2016Renewal fee patent year 07
20.02.2017Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.02.2010
AT05.04.2017
CY05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
IT05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
MK05.04.2017
NL05.04.2017
PL05.04.2017
PT05.04.2017
RO05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
TR05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
[2020/31]
Former [2020/27]HU05.02.2010
AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
IT05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
NL05.04.2017
PL05.04.2017
PT05.04.2017
RO05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
TR05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2020/15]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
IT05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
TR05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2018/44]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
IT05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2018/25]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
IT05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2018/11]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
IT05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
SE05.04.2017
SK05.04.2017
SM05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2018/10]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
SE05.04.2017
SK05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2018/09]AT05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
SE05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2017/50]AT05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
SE05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2017/49]AT05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
NL05.04.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2017/48]NL05.04.2017
Documents cited:Search[XI]EP0394026  (RIKER LABORATORIES INC [US]) [X] 1,5,7,11,13,15 * page 2, line 34 - line 37 * * page 2, line 54 - page 3, line 3 * * examples 1,2,16 * [I] 2-4,6,8-10,12,14,16-19;
 [XI]US2007264317  (YOSHA IDO [IL], et al) [X] 1,5,7,11,13,15 * paragraph [0029]; example 6; table 6 * [I] 2-4,6,8-10,12,14,16-19;
 [XI]US2008207674  (STOESZ JAMES D [US], et al) [X] 1,4,5,7,11,13,15 * page 3 - page 4; tables 3-4 * * examples 13-18 * * paragraph [0041] * [I] 2,3,6,8-10,12,14,16-19;
 [XI]WO2008118763  (GRACEWAY PHARMACEUTICALS LLC [US], et al) [X] 1,5,7,11,13,15 * page 1, paragraph 1 * * page 26; example 16 * [I] 2-4,6,8-10,12,14,16-19;
 [XP]WO2009091541  (DOW PHARMACEUTICAL SCIENCES [US], et al) [XP] 1,3,5,6,11,13,15,17,18 * page 1, paragraph 2 - paragraph 3 * * examples 1,5-9; tables 1,12,14-17 * * page 12, paragraph L - page 13, paragraph 1 *;
 [A]  - SMITH ET AL, "Antitumor Effects of Imidazoquinolines in Urothelial Cell Carcinoma of the Bladder", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, (20070514), vol. 177, no. 6, ISSN 0022-5347, pages 2347 - 2351, XP022078754 [A] 1-19 * page 2351, column L, line 18 - line 25 *

DOI:   http://dx.doi.org/10.1016/j.juro.2007.01.112
 [A]  - CHANG YUCHI C ET AL, "Current and potential uses of imiquimod", SOUTHERN MEDICAL JOURNAL, SOUTHERN MEDICAL ASSOCIATION, US, (200509), vol. 98, no. 9, doi:10.1097/01.SMJ.0000176712.01491.98, ISSN 0038-4348, pages 913 - 919, XP009092172 [A] 1-19 * the whole document *

DOI:   http://dx.doi.org/10.1097/01.SMJ.0000176712.01491.98
 [A]  - HENGGE U ET AL, "Topical immunomodulators-progress towards treating inflammation, infection, and cancer", LANCET INFECTIOUS DISEASES, ELSEVIER LTD, US, (200110), vol. 1, no. 3, doi:10.1016/S1473-3099(01)00095-0, ISSN 1473-3099, pages 189 - 198, XP004812198 [A] 1-19 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1473-3099(01)00095-0
 [A]  - GILLES DUMORTIER ET AL, "A Review of Poloxamer 407 Pharmaceutical and Pharmacological Characteristics", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, (20061111), vol. 23, no. 12, doi:10.1007/S11095-006-9104-4, ISSN 1573-904X, pages 2709 - 2728, XP019453318 [A] 1-19 * the whole document *

DOI:   http://dx.doi.org/10.1007/s11095-006-9104-4
by applicant   - HASAN ET AL., THE JOURNAL OF IMMUNOLOGY, (2005), vol. 174, pages 2942 - 2950
    - KAWAI, T.; S. AKIRA, "TLR signalling.", CELL DEATH DIFFER, (2006), vol. 13, no. 5, pages 816 - 25
    - PURDON CH; AZZI CG; ZHANG J; SMITH EW; MAIBACH HI, "Penetration enhancement of transdermal delivery-current permutations and limitations", CRIT REV THER DRUG CARRIER SYST., (2004), vol. 21, pages 97 - 132
    - CHANG YC; MADKAN V; COOK-NORRIS R; SRA K; TYRING S., "Current and potential uses of imiquimod.", SOUTH MED J., (2005), vol. 98, pages 914 - 20
    - WAGSTAFF AJ; PERRY CM, "Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions", DRUGS, (2007), vol. 67, doi:doi:10.2165/00003495-200767150-00006, pages 2187 - 210, XP009158526

DOI:   http://dx.doi.org/10.2165/00003495-200767150-00006
    - WAGSTAFF AJ; PERRY CM, "Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.", DRUGS, (2007), vol. 67, doi:doi:10.2165/00003495-200767150-00006, pages 2187 - 210, XP009158526

DOI:   http://dx.doi.org/10.2165/00003495-200767150-00006
    - BARNETSON RS; SATCHELL A; ZHUANG L; SLADE HB; HALLIDAY GM, "Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells", CLINICAL AND EXPERIMENTAL DERMATOLOGY, (2004), vol. 29, pages 639 - 43
    - SMITH EB; SCHWARTZ M; KAWAMOTO H ET AL., "Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder", THE JOURNAL OF UROLOGY, (2007), vol. 177, doi:doi:10.1016/j.juro.2007.01.112, pages 2347 - 51, XP022078754

DOI:   http://dx.doi.org/10.1016/j.juro.2007.01.112
    - SMITH EB; SCHWARTZ M; KAWAMOTO H ET AL., "Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder", THEJOURNAL OF UROLOGY, (2007), vol. 177, doi:doi:10.1016/j.juro.2007.01.112, pages 2347 - 51, XP022078754

DOI:   http://dx.doi.org/10.1016/j.juro.2007.01.112
    - SMITH EB; SCHWARTZ M; KAWAMOTO H ET AL., "Antitumour effects of Imidazoquinolines in urothelial cell carcinoma of the bladder", J UROL, (2007), vol. 177, doi:doi:10.1016/j.juro.2007.01.112, page 2347, XP022078754

DOI:   http://dx.doi.org/10.1016/j.juro.2007.01.112
    - LIU H; SCHWARTZ MJ; HWANG DH; SCHERR OS, "Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma", BJU INT, (2008), vol. 101, pages 894 - 901
    - LIU H; SCHWARTZ MJ; HWANG DH; SCHERR OS., "Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma.", BJU INT, (2008), vol. 101, pages 894 - 901
    - SCHENK-BRAAT EA; BANGMA CH., "Immunotherapy for superficial bladder cancer", CANCER IMMUNOLLMMUNOTHER., (2005), vol. 54, doi:doi:10.1007/s00262-004-0621-x, pages 414 - 23, XP019333125

DOI:   http://dx.doi.org/10.1007/s00262-004-0621-x
    - ALEXANDROFF AB; JACKSON AM; O'DONNELL MA; JAMES K., "BCG immunotherapy of bladder cancer: 20 years on.", LANCET, (1999), vol. 353, doi:doi:10.1016/S0140-6736(98)07422-4, pages 1689 - 94, XP005062272

DOI:   http://dx.doi.org/10.1016/S0140-6736(98)07422-4
    - DE JAGER R; GUINAN P; LAMM D ET AL., "Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials", UROLOGY, (1991), vol. 38, doi:doi:10.1016/0090-4295(91)80166-5, pages 507 - 13, XP023311653

DOI:   http://dx.doi.org/10.1016/0090-4295(91)80166-5
    - TOTTERMAN TH; LOSKOG A; ESSAND M., "The immunotherapy of prostate and bladder cancer", BJU INTERNATIONAL., (2005), vol. 96, pages 728 - 35
    - DE BOER EC; ROOIJAKKERS SJ; SCHAMHART DH; KURTH KH, "Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.", THE JOURNAL OF UROLOGY, (2003), vol. 170, doi:doi:10.1097/01.ju.0000091826.83705.79, pages 2004 - 8, XP005532931

DOI:   http://dx.doi.org/10.1097/01.ju.0000091826.83705.79
    - SUTTMANN H; RIEMENSBERGER J; BENTIEN G ET AL., "Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses", CANCER RESEARCH, (2006), vol. 66, pages 8250 - 7
    - SIMONS MP; O'DONNELL MA; GRIFFITH TS, "Role of neutrophils in BCG immunotherapy for bladder cancer", UROLOGIC ONCOLOGY, (2008), vol. 26, doi:doi:10.1016/j.urolonc.2007.11.031, pages 341 - 5, XP022796279

DOI:   http://dx.doi.org/10.1016/j.urolonc.2007.11.031
    - BOHLE A; BRANDAU S., "Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer", THE JOURNAL OF UROLOGY, (2003), vol. 170, doi:doi:10.1097/01.ju.0000073852.24341.4a, pages 964 - 9, XP005533049

DOI:   http://dx.doi.org/10.1097/01.ju.0000073852.24341.4a
    - BABJUK M; OOSTERLINCK W; SYLVESTER R; KAASINEN E; BOHLE A; PALOU-REDORTA J, "European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.", EUR UROL, (2008), vol. 54, pages 303 - 14
    - BABJUK M; OOSTERLINCK W; SYLVESTER R; KAASINEN E; BOH[E A; PALOU-REDORTA J, "European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder", EUR UROL, (2008), vol. 54, pages 303 - 14
    - WITJES JA; PALOU J; SOLOWAY M; LAMM 0; BRAUSI M; SPERMON JR; PERSAD R; BUCKLEY R; AKAZA H; COLOMBEL M, "Clinical Practice recommendations for the prevention and management of intravesical therapy-associated adverse events", EUR. UROL, (2008), vol. 7, doi:doi:10.1016/j.eursup.2008.08.001, pages 667 - 74, XP025408662

DOI:   http://dx.doi.org/10.1016/j.eursup.2008.08.001
    - SYLVESTER FJ; VAN DER MEIJDEN AP; LAMM DL, "intravesical bacillus Calmetie-Guerin reduces the risk of progression in patients with superficial bladder cancer: a metaanalysis of the published results of randomized clinical trials.", URO!, (2002), vol. 168, page 196470
    - MALMSTR6M PU; SYLVESTER RJ; CRAWFORD ED; FRIEDRICH M; KREGE S; RINTALA E; SOLSONA E; DI STASI SM; WITJES JA, "An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical Mitomycin C versus Bacillus Caimettte-Guerin for non-muscle-invasive bladder cancer", EUR UROL, (2009), vol. 56, no. 2, page 247256
    - A. CABANA. ET AL., "Study of the Gelation Process of Polyethylene Oxide-Polypropylene Oxide-Polyethylene Oxide Copolymer (Poloxamer 407) Aqueous Solutions", J. COLLOID INTERFACE SCI., (1997), vol. 190, pages 307 - 312
    - L. ZHANG, "Development and in-vitro evaluation of sustained release Poloxamer 407 (P407) gel formulations of ceftiofur", J. CONTROL. RELEASE, (2002), vol. 85, doi:doi:10.1016/S0168-3659(02)00273-0, pages 73 - 81, XP004397767

DOI:   http://dx.doi.org/10.1016/S0168-3659(02)00273-0
    - ZHANG O., CONTROL. RELEASE, (2002), vol. 85, pages 73 - 81
    - SCHON MP; SCHON M., "Imiquimod: mode of action.", BR J DERMATOL, (2007), vol. 157, pages 8 - 13
    - GEISSE J; CARO; LINDHOLM J; GOLITZ L; STAMPONE P; OWENS M, "Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies", J AM ACAD DERMATOL, (2004), vol. 50, doi:doi:10.1016/j.jaad.2003.11.066, pages 722 - 33, XP009060343

DOI:   http://dx.doi.org/10.1016/j.jaad.2003.11.066
    - WITT PL; RITCH PS; REDING D; MCAULIFFE TL; WESTRICK L; GROSSBERG SE; BORDEN EC, "Phase I trial of an oral immunomodulator and interferon inducer in cancer patients", CANCER RES, (1993), vol. 53, pages 5176 - 5180, XP002073162
    - HEGELE A; DALPKE A; BARTH P ET AL., "Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model", ANTICANCER RESEARCH., (2004), vol. 24, pages 2225 - 30
    - HAYASHI T; COTTAM HB; CHAN M ET AL., "Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7", AM J PHYSIOL REGULLNTEGR COMP PHYSIOL., (2008), vol. 295, pages R123 - 32
    - ALEXANDROFF AB; JACKSON AM; O'DONNELL MA; JAMES K, "BCG immunotherapy of bladder cancer: 20 years on", LANCET, (1999), vol. 353, doi:doi:10.1016/S0140-6736(98)07422-4, pages 1689 - 94, XP005062272

DOI:   http://dx.doi.org/10.1016/S0140-6736(98)07422-4
    - GAMES J., "Nursing implications in the management of superficial bladder cancer", SEMINARS IN UROLOGIC ONCOLOGY, (1996), vol. 14, pages 36 - 40
    - SMITH EB; SCHWARTZ M; KAWAMOTO H ET AL., "Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder", THE JOURNAL OF UROLOGY, (2007), vol. 177, pages 347 - 51
    - MANGSBO SM; NINALGA C; ESSAND M; LOSKOG A; TOTTERMAN TH, "CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-ell immunity", J IMMUNOTHER, (2008), vol. 31, pages 34 - 42
    - MANGSBO SM; NINALGA C; ESSAND M; LOSKOG A; TOTTERMAN TH, "CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity", J IMMUNOTHER, (2008), vol. 31, pages 34 - 42
    - SMITH EB; SCHWARTZ M; KAWAMOTO H ET AL., "Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder", THEJOURNALOF UROLOGY, (2007), vol. 177, doi:doi:10.1016/j.juro.2007.01.112, pages 2347 - 51, XP022078754

DOI:   http://dx.doi.org/10.1016/j.juro.2007.01.112
    - ATKINS H; DAVIES BR; KIRBY JA; KELLY JD, "Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG- containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy", BRITISH JOURNALOFCANCER, (2003), vol. 89, pages 2312 - 9
    - AKAZAWA T; MASUDA H; SAEKI Y ET AL., "Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice", CANCER RESEARCH, (2004), vol. 64, doi:doi:10.1158/0008-5472.CAN-03-1518, pages 757 - 64, XP002385329

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-03-1518
    - ANDERSON BC; PANDIT NK; MALLAPRAGADA SK, "Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels", J CONTROL RELEASE, (2001), vol. 70, doi:doi:10.1016/S0168-3659(00)00341-2, pages 157 - 67, XP055120086

DOI:   http://dx.doi.org/10.1016/S0168-3659(00)00341-2
    - BREWSTER ME; LOFTSSON T, "Cyclodextrins as pharmaceutical solubilizers", ADVANCED DRUG DELIVERY REVIEWS, (2007), vol. 59, pages 645 - 66
    - BILENSOY E; ROUF MA; VURAL I; SEN M; HINCAL AA, "Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole:beta-cyclodextrin complex", AAPS PHARMSCITECH., (2006), vol. 7, page E38
    - CHANG JY; OH YK; KONG HS ET AL., "Prolonged antifungal effects of clotrimazolecontaining mucoadhesive thermosensitive gels on vaginitis", J CONTROL RELEASE, (2002), vol. 82, doi:doi:10.1016/S0168-3659(02)00086-X, pages 39 - 50, XP004369788

DOI:   http://dx.doi.org/10.1016/S0168-3659(02)00086-X
    - SABAN MR; SIMPSON C; DAVIS C ET AL., "Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG", BMC IMMUNOLOGY, (2007), vol. 8, doi:doi:10.1186/1471-2172-8-6, page 6, XP021028155

DOI:   http://dx.doi.org/10.1186/1471-2172-8-6
    - LUO Y; CHEN X; O'DONELL MA, "Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect", CYTOKINE, (2003), vol. 21, doi:doi:10.1016/S1043-4666(02)00490-8, pages 17 - 26, XP002614769

DOI:   http://dx.doi.org/10.1016/S1043-4666(02)00490-8
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.